One of the most common questions in a Farmeci consultation is some version of how long until I see results? The honest answer is that Mounjaro (tirzepatide) does several different things on different timescales — and the bit you can see on the scale tends to lag behind the bits you can already feel. This article walks through what to expect week by week, why the first month often feels underwhelming, and when a clinician would actually start to worry that the medicine isn't doing what it should.
The first 24 to 72 hours
Tirzepatide is a once-weekly injection. After your first dose, the medicine starts acting on the gut and brain pathways that govern hunger, fullness and gastric emptying within hours. Most people report two things in the first two or three days: meals feel "smaller" — they get full faster — and the urge to snack between meals fades.
Plenty of people also notice mild nausea, a slightly off feeling, or some constipation in the first 24 to 48 hours. These are not signs the medicine isn't working. They are signs it is doing exactly what it's meant to: slowing down gastric emptying.
Weeks 1 to 4: the starter dose
Almost everyone in the UK starts at 2.5 mg once weekly for four weeks. This is a starter dose, not a therapeutic one. Its job is to let your body get used to tirzepatide without overwhelming you with side effects. Most people do not lose a lot of weight in this phase. Some lose nothing visible at all on the scale. That is normal.
What is usually happening underneath is a slow re-baselining of appetite. Cravings become quieter. You stop finishing every meal. The "background hum" of wanting to eat between meals gets turned down. Even if these changes don't show on the scale yet, they are the signal that the medicine is engaging with your physiology.
Weeks 4 to 12: when weight loss usually picks up
At about the four-week mark, most patients step up to 5 mg with their clinician's approval. This is typically when the curve on the scale starts to bend. The reason is partly biological — 5 mg is closer to a therapeutic dose — and partly behavioural, because by this point appetite changes have been in place long enough to alter actual eating patterns.
From here, weight loss tends to be steady rather than dramatic. A reasonable range is around 0.5 to 1 kg per week, although individuals vary widely. Some patients pause for a week or two and then resume; others move down steadily; a few see strong early loss and then a longer plateau. None of those patterns is wrong on its own.
Through weeks four to twelve, your clinician will be looking at the trend, not the noise. A weekly weigh-in can be useful if it helps you, but week-on-week variation is heavily affected by hydration, sleep and salt — the four-week moving average is more meaningful than any single reading.
Why the early weeks may feel underwhelming
If you came into treatment expecting fast visible weight loss in week one, the first month can be discouraging. A few honest things to say about that:
- The 2.5 mg starter dose is not what's been driving the famous weight-loss numbers in news stories — those usually reference patients on therapeutic doses.
- The body fights initial weight loss by holding onto fluid for a few weeks. Real fat loss can be partly masked by short-term water retention.
- The behavioural side takes time to settle. Eating differently for a week is different to having that as your new normal pattern.
- The numbers people quote online are often peak figures, not week-four figures.
The most useful frame for the first month is: am I noticing my appetite changing? If the answer is yes — quieter cravings, smaller portions, longer between meals — the medicine is doing its job, and the visible weight loss tends to follow.
When to talk to your clinician about no response
"No response" has a specific clinical meaning. It is not week three. It is closer to twelve weeks at a therapeutic dose with no meaningful change in weight, appetite or waist. If that is the picture at your review, your clinician will look at several things: your dose, your eating and sleep patterns, any other medications you're on, possible underlying conditions like hypothyroidism or PCOS, and whether there's a non-medication intervention that's missing.
It is also worth flagging early if your appetite has not changed at all in the first weeks. That is genuinely unusual on tirzepatide and worth a conversation, although it is rarely a reason to stop the medicine straight away.
Realistic expectations vs trial data
The SURMOUNT trial programme tested tirzepatide for weight management and produced the well-known average weight-loss percentages over 72 weeks. Two things are worth knowing about those numbers.
First, they are averages — the spread around the average is wide. Some trial participants lost more than the headline figure; some lost less. Second, the headline figures come from patients on full therapeutic doses for many months alongside lifestyle support. Comparing your week-four progress at 2.5 mg to a trial average at week seventy-two on 15 mg is comparing two very different situations.
A more useful expectation: in the first three months on Mounjaro with a clinician guiding you, most patients see noticeable appetite changes, steady weight loss once they reach 5 mg, and a clearer picture of how their body responds. The big-number outcomes most people associate with GLP-1 medications usually arrive over six to twelve months, not weeks.
Working with your Farmeci clinician
At each review your Farmeci clinician will look at three things together: your trend on the scale, what's changed for you in the way you eat and feel, and your side-effect picture. Honest answers about all three matter. If you've stalled but you're sleeping better, eating more protein and feeling stronger, that's a different conversation to "I haven't seen any change anywhere". The decision about whether to stay, step up, or step down at any given review is a joint one. Your clinician's job is to put the evidence and your experience together and make a sensible call.